Tumor cell kinase targets under concomitant thymalfasin + TKI therapy

Tumor cell kinase targets under concomitant thymalfasin + TKI therapy refers to a collective group of signaling proteins, primarily receptor tyrosine kinases (RTKs), that are targeted by small-molecule inhibitors in regimens supplemented by the immunomodulatory peptide thymalfasin (Thymosin alpha-1). Key kinases in this clinical context include the Vascular endothelial growth factor receptor (VEGFR) family, Epidermal growth factor receptor (EGFR), and Platelet-derived growth factor receptor (PDGFR), which are essential for tumor angiogenesis, survival, and proliferation [1, 2]. Thymalfasin is utilized as an adjuvant to enhance the host's immune surveillance, specifically by promoting the maturation of dendritic cells and the activation of cytotoxic T-lymphocytes through Toll-like receptor signaling [3, 5]. This combination therapy is most frequently explored in the treatment of advanced hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) to achieve synergistic anti-tumor effects and potentially mitigate the immunosuppressive effects of the tumor microenvironment [2, 4]. By simultaneously inhibiting oncogenic kinase signaling and stimulating anti-tumor immunity, this therapeutic approach aims for a more comprehensive reduction in tumor burden than monotherapy [1, 3].

Other names

Kinase targets in thymalfasin and tyrosine kinase inhibitor combination therapyTKI targets in thymosin alpha-1 augmented regimensReceptor tyrosine kinases in Tα1-TKI combination therapy

The mechanism involves the dual action of Tyrosine Kinase Inhibitors (TKIs) and thymalfasin. TKIs competitively inhibit the ATP-binding sites of specific kinases such as Vascular endothelial growth factor receptor (VEGFR), Epidermal growth factor receptor (EGFR), and Platelet-derived growth factor receptor (PDGFR), thereby blocking intracellular signaling pathways (e.g., MAPK/ERK, PI3K/Akt) that drive tumor growth and angiogenesis [1, 2]. Concurrently, thymalfasin (Thymosin alpha-1) acts as an immunomodulator by stimulating Toll-like receptors (TLR2 and TLR9), leading to the activation of dendritic cells, increased production of Th1 cytokines (e.g., IFN-gamma, IL-2), and the enhancement of T-cell and Natural Killer (NK) cell-mediated anti-tumor responses [3, 5].